{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:27:49Z","timestamp":1772800069471,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,5,2]],"date-time":"2001-05-02T00:00:00Z","timestamp":988761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data on all patients with acute lymphoblastic leukemia (ALL) aged 60 or older, referred to our institution over a 18\u2010year period, were studied to determine the incidence and range of clinical and biological subtypes, and the outcome of different therapeutic approaches. Sixty\u2010nine ALL cases (median age: 68 years) were diagnosed between 1980 and 1998 (18% of all adult ALL seen during this period). Ten of them (14%) had a past history of previous malignancy. Karyotypic analysis was performed successfully in 42 cases. Ten patients were diagnosed as Philadelphia chromosome positive (Ph<jats:sup>+<\/jats:sup>) ALL. Immunophenotyping was performed in 63 cases. Fifty\u2010six patients had B\u2010cell lineage ALL. T lymphoid markers were observed only in 5 cases. Co\u2010expression of myeloid markers was observed in 19% of tested cases. Five patients died before any chemotherapy could be given. All other patients received \u201ccurative\u201d treatment according to different protocols used during the period of study. Overall complete remission (CR) rate of these patients was 62% (95% confidence interval (CI): 50\u201374%). Thirty\u2010nine patients achieved CR after one course of chemotherapy and 4 patients after salvage therapy. Median disease\u2010free survival (DFS) of the entire cohort was 8.3 months (95% CI: 5\u201312.8 months) and median overall sur\u2010 vival was 7 months (95% CI: 6\u201310 months). In multivariate analysis, the presence of hemorrhage (<jats:italic>P<\/jats:italic> = 0.02) was a poor prognostic for CR achievement. Higher WHO performance status (<jats:italic>P<\/jats:italic> = 0.003) and the presence of hemorrhage (<jats:italic>P<\/jats:italic> = 0.01) at diagnosis were poor prognostics for overall survival. When patients were stratified into three groups according to the time of admission, survival appeared significantly longer for patients admitted between July 1992 and December 1998 (median overall survival at 10 months) than for patients admitted before July 1992 (<jats:italic>P<\/jats:italic> = 0.04). \u201cAge\u2010adapted\u201d therapy appeared superior to \u201cyoung adult\u2010like\u201d therapy in terms of CR rate (96% versus 60%; <jats:italic>P<\/jats:italic> = 0.007). However, \u201cage\u2010adapted\u201d therapy did not show any advantage in terms of DFS or overall survival, making the difference in CR rates questionable. We conclude that the pejorative overall outcome in elderly ALL points to the need for new therapeutic trials taking into account the specific characteristics of ALL in this age group. Am. J. Hematol. 67:73\u201383, 2001. \u00a9 2001 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.1083","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T20:24:15Z","timestamp":1030307055000},"page":"73-83","source":"Crossref","is-referenced-by-count":53,"title":["Acute lymphoblastic leukemia in the elderly: The Edouard Herriot hospital experience"],"prefix":"10.1002","volume":"67","author":[{"given":"Xavier","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoleta","family":"Olteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Charrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Lh\u00e9ritier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Pierre","family":"Magaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Fiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,5,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V64.1.267.267","article-title":"Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomised trial by Cancer and Leukaemia Group B","volume":"64","author":"Gottlieb AJ","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.1.38.38"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1200\/JCO.1985.3.8.1053","article-title":"Long\u2010term survival in adult acute lymphoblastic leukaemia: follow\u2010up of a Southeastern Cancer Study Group trial","volume":"3","author":"Omura GA","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V60.3.677.677","article-title":"Adolescent and adult acute lymphoblastic leukemia. Prognostic features and outcome of therapy. A study of 293 patients","volume":"60","author":"Baccarani M","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00424.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood.V80.7.1813.1813","article-title":"Acute lymphoblastic leukemia in patients aged 60 years and over: a population\u2010based study of incidence and outcome","volume":"80","author":"Taylor PRA","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900110302"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01696557"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04982.x"},{"key":"e_1_2_1_11_2","first-page":"1643","article-title":"Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25\u2010year period","volume":"9","author":"Ferrari A","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051761"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400780"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60377-8_104"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.11.2002"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_1_17_2","first-page":"249","article-title":"CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia","volume":"9","author":"Thomas X","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V84.5.1603.1603","article-title":"Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87)","volume":"84","author":"Boucheix C","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_19_2","first-page":"1","volume-title":"Supplement to an International System for Human Cytogenetic Nomenclature","author":"ISCN (International System for Human Cytogenetic Nomenclature)","year":"1991"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91706-Z"},{"key":"e_1_2_1_21_2","first-page":"221","article-title":"Induction massive et consolidation pr\u00e9coce des leuc\u00e9mies aigu\u00ebs lympho\u00efdes de l'adulte. Etude pilote de faisabilit\u00e9 et \u00e9volution lointaine","volume":"18","author":"Fiere D","year":"1989","journal-title":"Presse M\u00e9d"},{"key":"e_1_2_1_22_2","first-page":"125","volume-title":"Acute leukemias. Prognostic factors and treatment strategies","author":"Fiere D","year":"1987"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1990"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01834381"},{"issue":"1","key":"e_1_2_1_25_2","first-page":"227b","article-title":"Preliminary results of an age\u2010adapted protocol in elderly patients with acute lymphocytic leukemia (ALL)","volume":"94","author":"Delannoy A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_1_26_2","first-page":"270","article-title":"Intensive therapy in 100 patients with Ph1 and\/or BCR\/ABL positive acute lymphoblastic leukemia (ALL): first interim analysis of the French\u2010Belgian\u2010Australian LALA\u201094 trial","volume":"102","author":"Dombret H","year":"1998","journal-title":"Br J Haematol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/JCO.1983.1.8.462","article-title":"Treatment of acute lymphoblastic leukemia in adults: results of the L\u201010 and L\u201010M protocols","volume":"1","author":"Schauer P","year":"1983","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.V62.3.606.606","article-title":"Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults","volume":"62","author":"Stryckmans PA","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.5.1394.1394"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80206-9"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V32.4.507.507"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1988.6.6.1014","article-title":"A cause specific hazard rate analysis of prognostic factor among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969","volume":"6","author":"Gaynor J","year":"1988","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.123.123"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy","volume":"73","author":"Hussein KK","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04295.x"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057821"},{"key":"e_1_2_1_37_2","first-page":"45","article-title":"Cancer incidence in five continents. Comparability and quality of data","volume":"120","author":"Parkin DM","year":"1992","journal-title":"IACR Sci Publ"},{"issue":"1","key":"e_1_2_1_38_2","first-page":"215","article-title":"Acute lymphocytic leukemia (ALL) in the elderly: characteristics and outcome with the vincristine\u2013adriamycin\u2013dexamethasone (VAD) regimen","volume":"82","author":"Preti A","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049625"},{"key":"e_1_2_1_40_2","first-page":"196","article-title":"Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance","volume":"5","author":"Secker\u2010Walker LM","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02204.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695862"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90911-N"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.1991.9.5.777","article-title":"Recombinant interferon alpha given before and in combination with standard chemotherapy in children with acute lymphoblastic leukemia in first marrow relapse: a Pediatric Oncology Group pilot study","volume":"9","author":"Ochs J","year":"1991","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.1083","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.1083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:10:15Z","timestamp":1700403015000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1002\/ajh.1083"],"URL":"https:\/\/doi.org\/10.1002\/ajh.1083","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5,2]]}}}